Bugs and Drugs—the Gut Microbiome as Hidden Metabolic Organ and Its Role in Personalized Pharmacotherapeutics
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 21572
Special Issue Editors
2. Surgical Research Unit, OUH, Odense, Denmark
3. Department of Clinical Research, University of Southern Denmark (SDU), Odense, Denmark
Interests: capsule endoscopy; gastroenterology; collagenous colitis; microscopic colitis
Special Issues, Collections and Topics in MDPI journals
2. The Centre for Digestive Diseases, Endoklinika, Szczecin, Poland
Interests: capsule endoscopy; liver diseases; internal medicine; irritable bowel syndrome; gastrointestinal diseases
Special Issues, Collections and Topics in MDPI journals
Interests: microbiota; gut–brain axis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacomicrobiomics is a new, dynamically developing field of medicine. The microbiome enzyme apparatus contributing to the intestinal ecosystem is—at least—partially responsible for the metabolism of xenobiotics, including drugs and dietary supplements. This activity may lead to several enzymatic reactions potentially responsible for a given therapeutic effect or lack of drug efficacy. The metabolites of the intestinal microbiota may compete with drugs for enzymes or receptors involved in therapeutic pathways of common medicines.
Recently, consumption of commonly used drugs designed to target human cells and prescribed by psychiatrists, gastroenterologists, diabetologists, and other medical professionals has been shown to possess a high potential to alter the composition and function of intestinal microbes. Additionally, gut microbiota shape the response of anticancer therapies and serve as a target to enhance their efficacy and minimize drug toxicity. As gut microbes also shape the structure and function of the gut barrier, it is plausible that even minor and subclinical drug–microbe-mediated injury to intestinal mucosa can result in significant, tough delayed, metabolic consequences, which may seriously affect the health of an individual. Therapies aimed at microbiota modulation—e.g., probiotics, prebiotics, fecal microbiota transplantation or non-absorbable antibiotics (rifaximin)—serve as effective tools to support the gut microbiome and optimize the use of various pharmaceuticals. Further, expanding the basic and clinical knowledge on drug–microbiome interaction to predict either beneficial or harmful outcomes is important and of interest to most contemporary healthcare professionals.
With this Special Issue in the Journal of Clinical Medicine, entitled “Bugs and Drugs - The Gut Microbiome as a Hidden Metabolic Organ and Its Role in Personalized Pharmacotherapeutics”, we focus on studies exploring the amazing interactions between gut microbes and the variety of medicine and dietary supplements commonly used in everyday clinical practice. We invite authors to share the results of their research. We welcome original and review papers on topics related to pharmacotherapy or any other therapeutic modalities with the potential to influence and interact with gut microbiota. Last but not least, therapies aimed at improving the metabolic status of an individual through microbiota modulation are welcome.
Dr. Anastasios Koulaouzidis
Dr. Wojciech Marlicz
Dr. Karolina Skonieczna-Żydecka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Microbiome
- Small bowel
- Pharmacomicrobiomics
- Xenobiotics
- Metabolome
- Probiotics
- Psychobiome
- Gut–brain axis
- Metabolism
- Obesity
- Cancer
- Checkpoint inhibitors
- Inflammasomes
- Exposome
- Fecal microbiota transplantation
- Duodenal mucosal resurfacing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
